The EPiGEN technology is based on a specific epigenetic biomarker's ability to predict the likely response to chemotherapy and/or radiotherapy applied to patients with Non-Small Cell Lung Cancer in advanced stages. The base technology, initially identified by researchers from the University Hospital of La Paz in Madrid, has been licensed by igen to turn it into a ready-to-use diagnostic kit that allows effective detection of the biomarker, providing an objective tool for the oncologist to personalize treatment of this type of cancer.
Diseñado por sitelicon.com
